Plasma histamine and catecholamine levels during hypotension induced by morphine and compound 48/80.
Histamine receptors are present in adrenergic terminals, and histamine is reported to inhibit release of the neurotransmitter norepinephrine (NE) at certain neuroeffector junctions. However, a physiological role for histamine in modifying adrenergic neurotransmission has not been established. To examine the interaction of elevated plasma histamine and catecholamine release, two compounds that release histamine, morphine (3 mg/kg), and compound 48/80 (0.5 mg/kg), were administered intravenously (i.v.). Plasma norepinephrine (NE) levels were used to monitor sympathetic nervous system activity, and plasma epinephrine (Epi) levels were used to monitor adrenal activity. Both morphine and compound 48/80 caused an immediate and marked increase in plasma histamine. Simultaneous with this increase, a marked decrease in mean arterial pressure occurred. Plasma NE levels increased in animals administered compound 48/80, but in morphine-treated animals, plasma NE levels did not change from pretreatment values. Plasma Epi levels increased in both groups, but the magnitude and duration of the responses differed. The results indicate that elevated plasma catecholamines can increase in response to histamine-induced hypotension but this effect can be suppressed by the central actions of morphine.
D000818:Animals; D004285:Dogs; D004837:Epinephrine / Q000097:blood*; D005260:Female; D006632:Histamine / Q000097:blood*; D007022:Hypotension / Q000097:blood* / Q000139:chemically induced; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009638:Norepinephrine / Q000097:blood*; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D003189:p-Methoxy-N-methylphenethylamine; D009020:Morphine; D006632:Histamine; D009638:Norepinephrine; D004837:Epinephrine